 | • レポートコード：GIR-107A15038 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、123ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、非腫瘍学バイオ医薬品のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。非腫瘍学バイオ医薬品の種類別市場規模（生物製剤、バイオシミラー）、用途別市場規模（免疫、内分泌、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・非腫瘍学バイオ医薬品の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Roche、Sanofi、Johnson & Johnson、Pfizer、Novo Nordisk、Novartis、Merck、Teva、Eli Lilly、Bristol-Myers Squibb、GlaxoSmithKline、UCB Pharma、Amgen、AbbVie、Takeda、AstraZeneca、Mylan、LEO Pharma、Boehringer Ingelheim、Alexion Pharmaceuticals、Elusys Therapeutics、Swedish Orphan Biovitrum、Biogen ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：生物製剤、バイオシミラー ・用途別分析2016年-2026年：免疫、内分泌、その他 ・非腫瘍学バイオ医薬品の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・非腫瘍学バイオ医薬品のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・非腫瘍学バイオ医薬品のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・非腫瘍学バイオ医薬品の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・非腫瘍学バイオ医薬品の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Non-oncology Biopharmaceuticals market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Non-oncology Biopharmaceuticals size is estimated to be USD 412960 million in 2026 from USD 304180 million in 2020, with a change XX% between 2020 and 2021. The global Non-oncology Biopharmaceuticals market size is expected to grow at a CAGR of 7.9% for the next five years.
Market segmentation
Non-oncology Biopharmaceuticals market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Biologics
Biosimilars
Market segment by Application, can be divided into
Immunology
Endocrinology
Others
Market segment by players, this report covers
Roche
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Novartis
Merck
Teva
Eli Lilly
Bristol-Myers Squibb
GlaxoSmithKline
UCB Pharma
Amgen
AbbVie
Takeda
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
Swedish Orphan Biovitrum
Biogen
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Non-oncology Biopharmaceuticals
1.2 Classification of Non-oncology Biopharmaceuticals by Type
1.2.1 Overview: Global Non-oncology Biopharmaceuticals Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Type in 2020
1.2.3 Biologics
1.2.4 Biosimilars
1.3 Global Non-oncology Biopharmaceuticals Market by Application
1.3.1 Overview: Global Non-oncology Biopharmaceuticals Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Immunology
1.3.3 Endocrinology
1.3.4 Others
1.4 Global Non-oncology Biopharmaceuticals Market Size & Forecast
1.5 Global Non-oncology Biopharmaceuticals Market Size and Forecast by Region
1.5.1 Global Non-oncology Biopharmaceuticals Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Non-oncology Biopharmaceuticals Market Size by Region, (2016-2021)
1.5.3 North America Non-oncology Biopharmaceuticals Market Size and Prospect (2016-2026)
1.5.4 Europe Non-oncology Biopharmaceuticals Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Non-oncology Biopharmaceuticals Market Size and Prospect (2016-2026)
1.5.6 South America Non-oncology Biopharmaceuticals Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Non-oncology Biopharmaceuticals Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Non-oncology Biopharmaceuticals Market Drivers
1.6.2 Non-oncology Biopharmaceuticals Market Restraints
1.6.3 Non-oncology Biopharmaceuticals Trends Analysis
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Non-oncology Biopharmaceuticals Product and Solutions
2.1.4 Roche Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Roche Recent Developments and Future Plans
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Non-oncology Biopharmaceuticals Product and Solutions
2.2.4 Sanofi Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Sanofi Recent Developments and Future Plans
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business
2.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Product and Solutions
2.3.4 Johnson & Johnson Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Johnson & Johnson Recent Developments and Future Plans
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Non-oncology Biopharmaceuticals Product and Solutions
2.4.4 Pfizer Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Pfizer Recent Developments and Future Plans
2.5 Novo Nordisk
2.5.1 Novo Nordisk Details
2.5.2 Novo Nordisk Major Business
2.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Product and Solutions
2.5.4 Novo Nordisk Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Novo Nordisk Recent Developments and Future Plans
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Non-oncology Biopharmaceuticals Product and Solutions
2.6.4 Novartis Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Novartis Recent Developments and Future Plans
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck Non-oncology Biopharmaceuticals Product and Solutions
2.7.4 Merck Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Merck Recent Developments and Future Plans
2.8 Teva
2.8.1 Teva Details
2.8.2 Teva Major Business
2.8.3 Teva Non-oncology Biopharmaceuticals Product and Solutions
2.8.4 Teva Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Teva Recent Developments and Future Plans
2.9 Eli Lilly
2.9.1 Eli Lilly Details
2.9.2 Eli Lilly Major Business
2.9.3 Eli Lilly Non-oncology Biopharmaceuticals Product and Solutions
2.9.4 Eli Lilly Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Eli Lilly Recent Developments and Future Plans
2.10 Bristol-Myers Squibb
2.10.1 Bristol-Myers Squibb Details
2.10.2 Bristol-Myers Squibb Major Business
2.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product and Solutions
2.10.4 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.11 GlaxoSmithKline
2.11.1 GlaxoSmithKline Details
2.11.2 GlaxoSmithKline Major Business
2.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Product and Solutions
2.11.4 GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 GlaxoSmithKline Recent Developments and Future Plans
2.12 UCB Pharma
2.12.1 UCB Pharma Details
2.12.2 UCB Pharma Major Business
2.12.3 UCB Pharma Non-oncology Biopharmaceuticals Product and Solutions
2.12.4 UCB Pharma Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 UCB Pharma Recent Developments and Future Plans
2.13 Amgen
2.13.1 Amgen Details
2.13.2 Amgen Major Business
2.13.3 Amgen Non-oncology Biopharmaceuticals Product and Solutions
2.13.4 Amgen Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Amgen Recent Developments and Future Plans
2.14 AbbVie
2.14.1 AbbVie Details
2.14.2 AbbVie Major Business
2.14.3 AbbVie Non-oncology Biopharmaceuticals Product and Solutions
2.14.4 AbbVie Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 AbbVie Recent Developments and Future Plans
2.15 Takeda
2.15.1 Takeda Details
2.15.2 Takeda Major Business
2.15.3 Takeda Non-oncology Biopharmaceuticals Product and Solutions
2.15.4 Takeda Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Takeda Recent Developments and Future Plans
2.16 AstraZeneca
2.16.1 AstraZeneca Details
2.16.2 AstraZeneca Major Business
2.16.3 AstraZeneca Non-oncology Biopharmaceuticals Product and Solutions
2.16.4 AstraZeneca Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 AstraZeneca Recent Developments and Future Plans
2.17 Mylan
2.17.1 Mylan Details
2.17.2 Mylan Major Business
2.17.3 Mylan Non-oncology Biopharmaceuticals Product and Solutions
2.17.4 Mylan Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Mylan Recent Developments and Future Plans
2.18 LEO Pharma
2.18.1 LEO Pharma Details
2.18.2 LEO Pharma Major Business
2.18.3 LEO Pharma Non-oncology Biopharmaceuticals Product and Solutions
2.18.4 LEO Pharma Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 LEO Pharma Recent Developments and Future Plans
2.19 Boehringer Ingelheim
2.19.1 Boehringer Ingelheim Details
2.19.2 Boehringer Ingelheim Major Business
2.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Product and Solutions
2.19.4 Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.19.5 Boehringer Ingelheim Recent Developments and Future Plans
2.20 Alexion Pharmaceuticals
2.20.1 Alexion Pharmaceuticals Details
2.20.2 Alexion Pharmaceuticals Major Business
2.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product and Solutions
2.20.4 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.20.5 Alexion Pharmaceuticals Recent Developments and Future Plans
2.21 Elusys Therapeutics
2.21.1 Elusys Therapeutics Details
2.21.2 Elusys Therapeutics Major Business
2.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Product and Solutions
2.21.4 Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.21.5 Elusys Therapeutics Recent Developments and Future Plans
2.22 Swedish Orphan Biovitrum
2.22.1 Swedish Orphan Biovitrum Details
2.22.2 Swedish Orphan Biovitrum Major Business
2.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product and Solutions
2.22.4 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.22.5 Swedish Orphan Biovitrum Recent Developments and Future Plans
2.23 Biogen
2.23.1 Biogen Details
2.23.2 Biogen Major Business
2.23.3 Biogen Non-oncology Biopharmaceuticals Product and Solutions
2.23.4 Biogen Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021)
2.23.5 Biogen Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Non-oncology Biopharmaceuticals Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Non-oncology Biopharmaceuticals Players Market Share
3.2.2 Top 10 Non-oncology Biopharmaceuticals Players Market Share
3.2.3 Market Competition Trend
3.3 Non-oncology Biopharmaceuticals Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Non-oncology Biopharmaceuticals Revenue and Market Share by Type (2016-2021)
4.2 Global Non-oncology Biopharmaceuticals Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2016-2021)
5.2 Non-oncology Biopharmaceuticals Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Non-oncology Biopharmaceuticals Revenue by Type (2016-2026)
6.2 North America Non-oncology Biopharmaceuticals Revenue by Application (2016-2026)
6.3 North America Non-oncology Biopharmaceuticals Market Size by Country
6.3.1 North America Non-oncology Biopharmaceuticals Revenue by Country (2016-2026)
6.3.2 United States Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
6.3.3 Canada Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
6.3.4 Mexico Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Non-oncology Biopharmaceuticals Revenue by Type (2016-2026)
7.2 Europe Non-oncology Biopharmaceuticals Revenue by Application (2016-2026)
7.3 Europe Non-oncology Biopharmaceuticals Market Size by Country
7.3.1 Europe Non-oncology Biopharmaceuticals Revenue by Country (2016-2026)
7.3.2 Germany Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
7.3.3 France Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
7.3.5 Russia Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
7.3.6 Italy Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Type (2016-2026)
8.2 Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Application (2016-2026)
8.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region
8.3.1 Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Region (2016-2026)
8.3.2 China Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
8.3.3 Japan Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
8.3.4 South Korea Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
8.3.5 India Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
8.3.7 Australia Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Non-oncology Biopharmaceuticals Revenue by Type (2016-2026)
9.2 South America Non-oncology Biopharmaceuticals Revenue by Application (2016-2026)
9.3 South America Non-oncology Biopharmaceuticals Market Size by Country
9.3.1 South America Non-oncology Biopharmaceuticals Revenue by Country (2016-2026)
9.3.2 Brazil Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
9.3.3 Argentina Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Type (2016-2026)
10.2 Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Application (2016-2026)
10.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country
10.3.1 Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Country (2016-2026)
10.3.2 Turkey Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
10.3.4 UAE Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Non-oncology Biopharmaceuticals Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Non-oncology Biopharmaceuticals Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Non-oncology Biopharmaceuticals Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Non-oncology Biopharmaceuticals Revenue (USD Million) by Region (2016-2021)
Table 5. Global Non-oncology Biopharmaceuticals Revenue Market Share by Region (2021-2026)
Table 6. Roche Corporate Information, Head Office, and Major Competitors
Table 7. Roche Major Business
Table 8. Roche Non-oncology Biopharmaceuticals Product and Solutions
Table 9. Roche Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Sanofi Corporate Information, Head Office, and Major Competitors
Table 11. Sanofi Major Business
Table 12. Sanofi Non-oncology Biopharmaceuticals Product and Solutions
Table 13. Sanofi Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 15. Johnson & Johnson Major Business
Table 16. Johnson & Johnson Non-oncology Biopharmaceuticals Product and Solutions
Table 17. Johnson & Johnson Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Pfizer Corporate Information, Head Office, and Major Competitors
Table 19. Pfizer Major Business
Table 20. Pfizer Non-oncology Biopharmaceuticals Product and Solutions
Table 21. Pfizer Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Novo Nordisk Corporate Information, Head Office, and Major Competitors
Table 23. Novo Nordisk Major Business
Table 24. Novo Nordisk Non-oncology Biopharmaceuticals Product and Solutions
Table 25. Novo Nordisk Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Novartis Corporate Information, Head Office, and Major Competitors
Table 27. Novartis Major Business
Table 28. Novartis Non-oncology Biopharmaceuticals Product and Solutions
Table 29. Novartis Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Merck Corporate Information, Head Office, and Major Competitors
Table 31. Merck Major Business
Table 32. Merck Non-oncology Biopharmaceuticals Product and Solutions
Table 33. Merck Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Teva Corporate Information, Head Office, and Major Competitors
Table 35. Teva Major Business
Table 36. Teva Non-oncology Biopharmaceuticals Product and Solutions
Table 37. Teva Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 39. Eli Lilly Major Business
Table 40. Eli Lilly Non-oncology Biopharmaceuticals Product and Solutions
Table 41. Eli Lilly Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 43. Bristol-Myers Squibb Major Business
Table 44. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product and Solutions
Table 45. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 47. GlaxoSmithKline Major Business
Table 48. GlaxoSmithKline Non-oncology Biopharmaceuticals Product and Solutions
Table 49. GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. UCB Pharma Corporate Information, Head Office, and Major Competitors
Table 51. UCB Pharma Major Business
Table 52. UCB Pharma Non-oncology Biopharmaceuticals Product and Solutions
Table 53. UCB Pharma Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Amgen Corporate Information, Head Office, and Major Competitors
Table 55. Amgen Major Business
Table 56. Amgen Non-oncology Biopharmaceuticals Product and Solutions
Table 57. Amgen Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. AbbVie Corporate Information, Head Office, and Major Competitors
Table 59. AbbVie Major Business
Table 60. AbbVie Non-oncology Biopharmaceuticals Product and Solutions
Table 61. AbbVie Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Takeda Corporate Information, Head Office, and Major Competitors
Table 63. Takeda Major Business
Table 64. Takeda Non-oncology Biopharmaceuticals Product and Solutions
Table 65. Takeda Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 67. AstraZeneca Major Business
Table 68. AstraZeneca Non-oncology Biopharmaceuticals Product and Solutions
Table 69. AstraZeneca Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Mylan Corporate Information, Head Office, and Major Competitors
Table 71. Mylan Major Business
Table 72. Mylan Non-oncology Biopharmaceuticals Product and Solutions
Table 73. Mylan Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. LEO Pharma Corporate Information, Head Office, and Major Competitors
Table 75. LEO Pharma Major Business
Table 76. LEO Pharma Non-oncology Biopharmaceuticals Product and Solutions
Table 77. LEO Pharma Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 79. Boehringer Ingelheim Major Business
Table 80. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product and Solutions
Table 81. Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 82. Alexion Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 83. Alexion Pharmaceuticals Major Business
Table 84. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product and Solutions
Table 85. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 86. Elusys Therapeutics Corporate Information, Head Office, and Major Competitors
Table 87. Elusys Therapeutics Major Business
Table 88. Elusys Therapeutics Non-oncology Biopharmaceuticals Product and Solutions
Table 89. Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 90. Swedish Orphan Biovitrum Corporate Information, Head Office, and Major Competitors
Table 91. Swedish Orphan Biovitrum Major Business
Table 92. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product and Solutions
Table 93. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 94. Biogen Corporate Information, Head Office, and Major Competitors
Table 95. Biogen Major Business
Table 96. Biogen Non-oncology Biopharmaceuticals Product and Solutions
Table 97. Biogen Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 98. Global Non-oncology Biopharmaceuticals Revenue (USD Million) by Players (2019-2021)
Table 99. Global Non-oncology Biopharmaceuticals Revenue Share by Players (2019-2021)
Table 100. Breakdown of Non-oncology Biopharmaceuticals by Company Type (Tier 1, Tier 2 and Tier 3)
Table 101. Non-oncology Biopharmaceuticals Players Head Office, Products and Services Provided
Table 102. Non-oncology Biopharmaceuticals Mergers & Acquisitions in the Past Five Years
Table 103. Non-oncology Biopharmaceuticals New Entrants and Expansion Plans
Table 104. Global Non-oncology Biopharmaceuticals Revenue (USD Million) by Type (2016-2021)
Table 105. Global Non-oncology Biopharmaceuticals Revenue Share by Type (2016-2021)
Table 106. Global Non-oncology Biopharmaceuticals Revenue Forecast by Type (2021-2026)
Table 107. Global Non-oncology Biopharmaceuticals Revenue by Application (2016-2021)
Table 108. Global Non-oncology Biopharmaceuticals Revenue Forecast by Application (2021-2026)
Table 109. North America Non-oncology Biopharmaceuticals Revenue by Type (2016-2021) & (USD Million)
Table 110. North America Non-oncology Biopharmaceuticals Revenue by Type (2021-2026) & (USD Million)
Table 111. North America Non-oncology Biopharmaceuticals Revenue by Application (2016-2021) & (USD Million)
Table 112. North America Non-oncology Biopharmaceuticals Revenue by Application (2021-2026) & (USD Million)
Table 113. North America Non-oncology Biopharmaceuticals Revenue by Country (2016-2021) & (USD Million)
Table 114. North America Non-oncology Biopharmaceuticals Revenue by Country (2021-2026) & (USD Million)
Table 115. Europe Non-oncology Biopharmaceuticals Revenue by Type (2016-2021) & (USD Million)
Table 116. Europe Non-oncology Biopharmaceuticals Revenue by Type (2021-2026) & (USD Million)
Table 117. Europe Non-oncology Biopharmaceuticals Revenue by Application (2016-2021) & (USD Million)
Table 118. Europe Non-oncology Biopharmaceuticals Revenue by Application (2021-2026) & (USD Million)
Table 119. Europe Non-oncology Biopharmaceuticals Revenue by Country (2016-2021) & (USD Million)
Table 120. Europe Non-oncology Biopharmaceuticals Revenue by Country (2021-2026) & (USD Million)
Table 121. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Type (2016-2021) & (USD Million)
Table 122. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Type (2021-2026) & (USD Million)
Table 123. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Application (2016-2021) & (USD Million)
Table 124. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Application (2021-2026) & (USD Million)
Table 125. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Region (2016-2021) & (USD Million)
Table 126. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Region (2021-2026) & (USD Million)
Table 127. South America Non-oncology Biopharmaceuticals Revenue by Type (2016-2021) & (USD Million)
Table 128. South America Non-oncology Biopharmaceuticals Revenue by Type (2021-2026) & (USD Million)
Table 129. South America Non-oncology Biopharmaceuticals Revenue by Application (2016-2021) & (USD Million)
Table 130. South America Non-oncology Biopharmaceuticals Revenue by Application (2021-2026) & (USD Million)
Table 131. South America Non-oncology Biopharmaceuticals Revenue by Country (2016-2021) & (USD Million)
Table 132. South America Non-oncology Biopharmaceuticals Revenue by Country (2021-2026) & (USD Million)
Table 133. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Type (2016-2021) & (USD Million)
Table 134. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Type (2021-2026) & (USD Million)
Table 135. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Application (2016-2021) & (USD Million)
Table 136. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Application (2021-2026) & (USD Million)
Table 137. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Country (2016-2021) & (USD Million)
Table 138. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Non-oncology Biopharmaceuticals Picture
Figure 2. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type in 2020
Figure 3. Biologics
Figure 4. Biosimilars
Figure 5. Non-oncology Biopharmaceuticals Revenue Market Share by Application in 2020
Figure 6. Immunology Picture
Figure 7. Endocrinology Picture
Figure 8. Others Picture
Figure 9. Global Non-oncology Biopharmaceuticals Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Non-oncology Biopharmaceuticals Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Non-oncology Biopharmaceuticals Revenue Market Share by Region (2016-2026)
Figure 12. Global Non-oncology Biopharmaceuticals Revenue Market Share by Region in 2020
Figure 13. North America Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Middle East and Africa Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Non-oncology Biopharmaceuticals Market Drivers
Figure 19. Non-oncology Biopharmaceuticals Market Restraints
Figure 20. Non-oncology Biopharmaceuticals Market Trends
Figure 21. Roche Recent Developments and Future Plans
Figure 22. Sanofi Recent Developments and Future Plans
Figure 23. Johnson & Johnson Recent Developments and Future Plans
Figure 24. Pfizer Recent Developments and Future Plans
Figure 25. Novo Nordisk Recent Developments and Future Plans
Figure 26. Novartis Recent Developments and Future Plans
Figure 27. Merck Recent Developments and Future Plans
Figure 28. Teva Recent Developments and Future Plans
Figure 29. Eli Lilly Recent Developments and Future Plans
Figure 30. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 31. GlaxoSmithKline Recent Developments and Future Plans
Figure 32. UCB Pharma Recent Developments and Future Plans
Figure 33. Amgen Recent Developments and Future Plans
Figure 34. AbbVie Recent Developments and Future Plans
Figure 35. Takeda Recent Developments and Future Plans
Figure 36. AstraZeneca Recent Developments and Future Plans
Figure 37. Mylan Recent Developments and Future Plans
Figure 38. LEO Pharma Recent Developments and Future Plans
Figure 39. Boehringer Ingelheim Recent Developments and Future Plans
Figure 40. Alexion Pharmaceuticals Recent Developments and Future Plans
Figure 41. Elusys Therapeutics Recent Developments and Future Plans
Figure 42. Swedish Orphan Biovitrum Recent Developments and Future Plans
Figure 43. Biogen Recent Developments and Future Plans
Figure 44. Global Non-oncology Biopharmaceuticals Revenue Share by Players in 2020
Figure 45. Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 46. Global Top 3 Players Non-oncology Biopharmaceuticals Revenue Market Share in 2020
Figure 47. Global Top 10 Players Non-oncology Biopharmaceuticals Revenue Market Share in 2020
Figure 48. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 49. Global Non-oncology Biopharmaceuticals Revenue Share by Type in 2020
Figure 50. Global Non-oncology Biopharmaceuticals Market Share Forecast by Type (2021-2026)
Figure 51. Global Non-oncology Biopharmaceuticals Revenue Share by Application in 2020
Figure 52. Global Non-oncology Biopharmaceuticals Market Share Forecast by Application (2021-2026)
Figure 53. North America Non-oncology Biopharmaceuticals Sales Market Share by Type (2016-2026)
Figure 54. North America Non-oncology Biopharmaceuticals Sales Market Share by Application (2016-2026)
Figure 55. North America Non-oncology Biopharmaceuticals Revenue Market Share by Country (2016-2026)
Figure 56. United States Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Canada Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Mexico Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Europe Non-oncology Biopharmaceuticals Sales Market Share by Type (2016-2026)
Figure 60. Europe Non-oncology Biopharmaceuticals Sales Market Share by Application (2016-2026)
Figure 61. Europe Non-oncology Biopharmaceuticals Revenue Market Share by Country (2016-2026)
Figure 62. Germany Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. France Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. United Kingdom Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Russia Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Italy Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Asia-Pacific Non-oncology Biopharmaceuticals Sales Market Share by Type (2016-2026)
Figure 68. Asia-Pacific Non-oncology Biopharmaceuticals Sales Market Share by Application (2016-2026)
Figure 69. Asia-Pacific Non-oncology Biopharmaceuticals Revenue Market Share by Region (2016-2026)
Figure 70. China Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Japan Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. South Korea Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. India Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Southeast Asia Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Australia Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. South America Non-oncology Biopharmaceuticals Sales Market Share by Type (2016-2026)
Figure 77. South America Non-oncology Biopharmaceuticals Sales Market Share by Application (2016-2026)
Figure 78. South America Non-oncology Biopharmaceuticals Revenue Market Share by Country (2016-2026)
Figure 79. Brazil Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Argentina Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Middle East and Africa Non-oncology Biopharmaceuticals Sales Market Share by Type (2016-2026)
Figure 82. Middle East and Africa Non-oncology Biopharmaceuticals Sales Market Share by Application (2016-2026)
Figure 83. Middle East and Africa Non-oncology Biopharmaceuticals Revenue Market Share by Country (2016-2026)
Figure 84. Turkey Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 85. Saudi Arabia Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 86. UAE Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 87. Methodology
Figure 88. Research Process and Data Source
がんバイオシミラー市場：世界及び中国市場分析・予測（～2024年） Oncology Biosimilars Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Oncology Biosimilars industry with a focus on the Chinese market. The report provides key statistics on the market status of the Oncology Biosimilars manufac…- 世界の血液腫瘍検査市場 2021：企業別、地域別、種類・用途別 The Hemato Oncology Testing market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…
- 世界の腫瘍用小分子薬剤市場 2021：企業別、地域別、種類・用途別 The Oncology Small Molecule Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade r…
- 世界の免疫腫瘍学アッセイ市場予測（～2024年）：企業別、地域別、種類・用途別 Immuno-Oncology Assays Accelerate Cancer Immunotherapy enable fast, effective, and clinically relevant understanding of immuno-oncology targets, pathways and mechanisms, enabling quicker development of immuno-oncology drugs. Learn how you can rapidly screen and develop antibodies targeting checkpoin…
- 世界の腫瘍ジェネリック注射薬市場 2021：企業別、地域別、種類・用途別 The Oncology Generic Injectable Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, tra…